nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—Abnormal chest sounds NOS—Lisinopril—dilated cardiomyopathy	0.0514	0.103	CcSEcCtD
Cladribine—NR5A1—Transcriptional regulation of pluripotent stem cells—ZIC3—dilated cardiomyopathy	0.0477	0.157	CbGpPWpGaD
Cladribine—PNP—Purine catabolism—GPX1—dilated cardiomyopathy	0.0204	0.0668	CbGpPWpGaD
Cladribine—RRM2B—cardiac ventricle—dilated cardiomyopathy	0.0195	0.105	CbGeAlD
Cladribine—Breath sounds abnormal—Lisinopril—dilated cardiomyopathy	0.0193	0.0387	CcSEcCtD
Cladribine—POLE3—cardiac ventricle—dilated cardiomyopathy	0.0185	0.099	CbGeAlD
Cladribine—RRM2B—myocardium—dilated cardiomyopathy	0.0184	0.0985	CbGeAlD
Cladribine—POLE3—myocardium—dilated cardiomyopathy	0.0174	0.0931	CbGeAlD
Cladribine—Infarction—Lisinopril—dilated cardiomyopathy	0.0133	0.0268	CcSEcCtD
Cladribine—RRM2B—heart—dilated cardiomyopathy	0.0128	0.0687	CbGeAlD
Cladribine—SLC22A2—Organic cation transport—SLC22A5—dilated cardiomyopathy	0.0128	0.0419	CbGpPWpGaD
Cladribine—Metabolic acidosis—Furosemide—dilated cardiomyopathy	0.0125	0.025	CcSEcCtD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.0123	0.0404	CbGpPWpGaD
Cladribine—Skin infection—Lisinopril—dilated cardiomyopathy	0.0122	0.0246	CcSEcCtD
Cladribine—POLE3—heart—dilated cardiomyopathy	0.0121	0.065	CbGeAlD
Cladribine—SLC22A1—Organic cation transport—SLC22A5—dilated cardiomyopathy	0.0119	0.0391	CbGpPWpGaD
Cladribine—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.0118	0.0238	CcSEcCtD
Cladribine—RRM2B—cardiac atrium—dilated cardiomyopathy	0.011	0.0588	CbGeAlD
Cladribine—PNP—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.0106	1	CbGdCrCtD
Cladribine—POLE3—cardiac atrium—dilated cardiomyopathy	0.0104	0.0556	CbGeAlD
Cladribine—RRM1—cardiac ventricle—dilated cardiomyopathy	0.00964	0.0516	CbGeAlD
Cladribine—POLE—heart—dilated cardiomyopathy	0.00925	0.0496	CbGeAlD
Cladribine—RRM1—myocardium—dilated cardiomyopathy	0.00907	0.0486	CbGeAlD
Cladribine—SLC22A2—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00867	0.0284	CbGpPWpGaD
Cladribine—SLC22A1—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00808	0.0265	CbGpPWpGaD
Cladribine—POLA1—heart—dilated cardiomyopathy	0.00797	0.0427	CbGeAlD
Cladribine—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00789	0.0158	CcSEcCtD
Cladribine—PNP—Purine metabolism—GPX1—dilated cardiomyopathy	0.00783	0.0257	CbGpPWpGaD
Cladribine—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00712	0.0143	CcSEcCtD
Cladribine—DCK—myocardium—dilated cardiomyopathy	0.00704	0.0377	CbGeAlD
Cladribine—Thrombosis—Furosemide—dilated cardiomyopathy	0.00696	0.014	CcSEcCtD
Cladribine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00671	0.0135	CcSEcCtD
Cladribine—RRM1—heart—dilated cardiomyopathy	0.00633	0.0339	CbGeAlD
Cladribine—Ataxia—Spironolactone—dilated cardiomyopathy	0.00618	0.0124	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00592	0.0119	CcSEcCtD
Cladribine—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00563	0.0113	CcSEcCtD
Cladribine—RRM1—cardiac atrium—dilated cardiomyopathy	0.00541	0.029	CbGeAlD
Cladribine—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00531	0.0107	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00502	0.0101	CcSEcCtD
Cladribine—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00502	0.0101	CcSEcCtD
Cladribine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00498	0.01	CcSEcCtD
Cladribine—DCK—heart—dilated cardiomyopathy	0.00492	0.0263	CbGeAlD
Cladribine—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00491	0.00987	CcSEcCtD
Cladribine—RRM2B—DNA Damage Response—FAS—dilated cardiomyopathy	0.00474	0.0156	CbGpPWpGaD
Cladribine—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00463	0.0093	CcSEcCtD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—FAS—dilated cardiomyopathy	0.00458	0.015	CbGpPWpGaD
Cladribine—RRM2B—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00454	0.0149	CbGpPWpGaD
Cladribine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.0043	0.00864	CcSEcCtD
Cladribine—DCK—cardiac atrium—dilated cardiomyopathy	0.0042	0.0225	CbGeAlD
Cladribine—Swelling—Furosemide—dilated cardiomyopathy	0.00406	0.00815	CcSEcCtD
Cladribine—Alopecia—Spironolactone—dilated cardiomyopathy	0.00402	0.00808	CcSEcCtD
Cladribine—Vascular purpura—Furosemide—dilated cardiomyopathy	0.004	0.00803	CcSEcCtD
Cladribine—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00396	0.00796	CcSEcCtD
Cladribine—PNP—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00394	0.0129	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00382	0.0125	CbGpPWpGaD
Cladribine—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00374	0.00752	CcSEcCtD
Cladribine—Purpura—Furosemide—dilated cardiomyopathy	0.00371	0.00746	CcSEcCtD
Cladribine—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.0037	0.00743	CcSEcCtD
Cladribine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00367	0.00738	CcSEcCtD
Cladribine—Lethargy—Furosemide—dilated cardiomyopathy	0.00365	0.00733	CcSEcCtD
Cladribine—Wheezing—Lisinopril—dilated cardiomyopathy	0.00359	0.00721	CcSEcCtD
Cladribine—Malaise—Spironolactone—dilated cardiomyopathy	0.00357	0.00717	CcSEcCtD
Cladribine—DCK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00346	0.0114	CbGpPWpGaD
Cladribine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00333	0.00669	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00331	0.0109	CbGpPWpGaD
Cladribine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00326	0.00655	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00322	0.00647	CcSEcCtD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00318	0.0104	CbGpPWpGaD
Cladribine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00317	0.00636	CcSEcCtD
Cladribine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00316	0.00634	CcSEcCtD
Cladribine—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00306	0.00615	CcSEcCtD
Cladribine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00299	0.006	CcSEcCtD
Cladribine—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00297	0.00597	CcSEcCtD
Cladribine—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00291	0.00584	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00289	0.00949	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.00288	0.00943	CbGpPWpGaD
Cladribine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00287	0.00577	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—GPX1—dilated cardiomyopathy	0.00284	0.00932	CbGpPWpGaD
Cladribine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00283	0.00569	CcSEcCtD
Cladribine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00282	0.00567	CcSEcCtD
Cladribine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00279	0.00561	CcSEcCtD
Cladribine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00276	0.00555	CcSEcCtD
Cladribine—ABCG2—heart—dilated cardiomyopathy	0.00274	0.0147	CbGeAlD
Cladribine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00274	0.0055	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00273	0.00549	CcSEcCtD
Cladribine—Renal failure—Furosemide—dilated cardiomyopathy	0.00271	0.00544	CcSEcCtD
Cladribine—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00268	0.00539	CcSEcCtD
Cladribine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00266	0.00535	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—FAS—dilated cardiomyopathy	0.00266	0.00873	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00261	0.00524	CcSEcCtD
Cladribine—Urticaria—Spironolactone—dilated cardiomyopathy	0.00257	0.00516	CcSEcCtD
Cladribine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00256	0.00513	CcSEcCtD
Cladribine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00252	0.00507	CcSEcCtD
Cladribine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00244	0.00491	CcSEcCtD
Cladribine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00243	0.00487	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00242	0.00486	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00241	0.00792	CbGpPWpGaD
Cladribine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00238	0.00478	CcSEcCtD
Cladribine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00234	0.0047	CcSEcCtD
Cladribine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00231	0.00465	CcSEcCtD
Cladribine—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.0023	0.00461	CcSEcCtD
Cladribine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00229	0.00459	CcSEcCtD
Cladribine—RRM1—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00226	0.00741	CbGpPWpGaD
Cladribine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00226	0.00454	CcSEcCtD
Cladribine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00225	0.00451	CcSEcCtD
Cladribine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00224	0.00449	CcSEcCtD
Cladribine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00221	0.00444	CcSEcCtD
Cladribine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00221	0.00444	CcSEcCtD
Cladribine—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.0022	0.00443	CcSEcCtD
Cladribine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00217	0.00436	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TUBB—dilated cardiomyopathy	0.00216	0.00708	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00216	0.00433	CcSEcCtD
Cladribine—Erythema—Furosemide—dilated cardiomyopathy	0.00215	0.00433	CcSEcCtD
Cladribine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00215	0.00433	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00215	0.00706	CbGpPWpGaD
Cladribine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00214	0.00429	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00213	0.00699	CbGpPWpGaD
Cladribine—Flatulence—Furosemide—dilated cardiomyopathy	0.00212	0.00426	CcSEcCtD
Cladribine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00208	0.00418	CcSEcCtD
Cladribine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00206	0.00413	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00205	0.00412	CcSEcCtD
Cladribine—Rash—Spironolactone—dilated cardiomyopathy	0.00204	0.00409	CcSEcCtD
Cladribine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00204	0.00409	CcSEcCtD
Cladribine—Renal failure—Lisinopril—dilated cardiomyopathy	0.00203	0.00409	CcSEcCtD
Cladribine—Headache—Spironolactone—dilated cardiomyopathy	0.00203	0.00407	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00202	0.00663	CbGpPWpGaD
Cladribine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00201	0.00404	CcSEcCtD
Cladribine—Anaemia—Furosemide—dilated cardiomyopathy	0.00199	0.004	CcSEcCtD
Cladribine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00196	0.00393	CcSEcCtD
Cladribine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00195	0.00392	CcSEcCtD
Cladribine—POLE2—Cell Cycle—EMD—dilated cardiomyopathy	0.00192	0.00631	CbGpPWpGaD
Cladribine—Nausea—Spironolactone—dilated cardiomyopathy	0.00192	0.00386	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00187	0.00612	CbGpPWpGaD
Cladribine—RRM2—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00186	0.0061	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.00185	0.00608	CbGpPWpGaD
Cladribine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00184	0.0037	CcSEcCtD
Cladribine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00183	0.00368	CcSEcCtD
Cladribine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00183	0.00368	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00182	0.00366	CcSEcCtD
Cladribine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00182	0.00366	CcSEcCtD
Cladribine—POLE2—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00181	0.00593	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—ANKRD1—dilated cardiomyopathy	0.00179	0.00585	CbGpPWpGaD
Cladribine—Confusional state—Furosemide—dilated cardiomyopathy	0.00177	0.00356	CcSEcCtD
Cladribine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00176	0.00353	CcSEcCtD
Cladribine—DCK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00174	0.0057	CbGpPWpGaD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00174	0.00569	CbGpPWpGaD
Cladribine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00172	0.00346	CcSEcCtD
Cladribine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00172	0.00346	CcSEcCtD
Cladribine—POLE2—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.00171	0.00561	CbGpPWpGaD
Cladribine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00171	0.00343	CcSEcCtD
Cladribine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.0017	0.00341	CcSEcCtD
Cladribine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00169	0.00338	CcSEcCtD
Cladribine—RRM2B—Metabolism—TAZ—dilated cardiomyopathy	0.00168	0.0055	CbGpPWpGaD
Cladribine—Anorexia—Furosemide—dilated cardiomyopathy	0.00168	0.00337	CcSEcCtD
Cladribine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00167	0.00336	CcSEcCtD
Cladribine—Chills—Lisinopril—dilated cardiomyopathy	0.00167	0.00335	CcSEcCtD
Cladribine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00166	0.00333	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00166	0.00544	CbGpPWpGaD
Cladribine—Hypotension—Furosemide—dilated cardiomyopathy	0.00164	0.0033	CcSEcCtD
Cladribine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00164	0.0033	CcSEcCtD
Cladribine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00163	0.00327	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00162	0.00531	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00162	0.00531	CbGpPWpGaD
Cladribine—Erythema—Lisinopril—dilated cardiomyopathy	0.00162	0.00325	CcSEcCtD
Cladribine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00162	0.00325	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00161	0.00529	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00161	0.00529	CbGpPWpGaD
Cladribine—Flatulence—Lisinopril—dilated cardiomyopathy	0.00159	0.0032	CcSEcCtD
Cladribine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00158	0.00317	CcSEcCtD
Cladribine—Back pain—Lisinopril—dilated cardiomyopathy	0.00156	0.00314	CcSEcCtD
Cladribine—Somnolence—Furosemide—dilated cardiomyopathy	0.00156	0.00314	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00156	0.0051	CbGpPWpGaD
Cladribine—PNP—Metabolism—ANKRD1—dilated cardiomyopathy	0.00155	0.00508	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00155	0.00507	CbGpPWpGaD
Cladribine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00153	0.00307	CcSEcCtD
Cladribine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00152	0.00305	CcSEcCtD
Cladribine—RRM2B—Metabolism—SDHA—dilated cardiomyopathy	0.00152	0.00498	CbGpPWpGaD
Cladribine—Fatigue—Furosemide—dilated cardiomyopathy	0.00152	0.00305	CcSEcCtD
Cladribine—Pain—Furosemide—dilated cardiomyopathy	0.0015	0.00302	CcSEcCtD
Cladribine—Constipation—Furosemide—dilated cardiomyopathy	0.0015	0.00302	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.0015	0.00492	CbGpPWpGaD
Cladribine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0015	0.00301	CcSEcCtD
Cladribine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00149	0.003	CcSEcCtD
Cladribine—Malaise—Lisinopril—dilated cardiomyopathy	0.00146	0.00293	CcSEcCtD
Cladribine—PNP—Metabolism—TAZ—dilated cardiomyopathy	0.00146	0.00477	CbGpPWpGaD
Cladribine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00145	0.00291	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TUBB—dilated cardiomyopathy	0.00145	0.00475	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00144	0.00474	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00144	0.00289	CcSEcCtD
Cladribine—Cough—Lisinopril—dilated cardiomyopathy	0.00141	0.00283	CcSEcCtD
Cladribine—POLE2—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.0014	0.00461	CbGpPWpGaD
Cladribine—Urticaria—Furosemide—dilated cardiomyopathy	0.0014	0.00281	CcSEcCtD
Cladribine—POLE—Cell Cycle—TUBB—dilated cardiomyopathy	0.00139	0.00456	CbGpPWpGaD
Cladribine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00139	0.00279	CcSEcCtD
Cladribine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00139	0.00279	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00139	0.00455	CbGpPWpGaD
Cladribine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00138	0.00276	CcSEcCtD
Cladribine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00138	0.00276	CcSEcCtD
Cladribine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00138	0.00276	CcSEcCtD
Cladribine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00137	0.00276	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00137	0.00275	CcSEcCtD
Cladribine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00136	0.00273	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00136	0.00445	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.00134	0.00439	CbGpPWpGaD
Cladribine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00133	0.00267	CcSEcCtD
Cladribine—POLA1—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.00132	0.00433	CbGpPWpGaD
Cladribine—Oedema—Lisinopril—dilated cardiomyopathy	0.00132	0.00265	CcSEcCtD
Cladribine—PNP—Metabolism—SDHA—dilated cardiomyopathy	0.00132	0.00432	CbGpPWpGaD
Cladribine—Infection—Lisinopril—dilated cardiomyopathy	0.00131	0.00263	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.0013	0.00427	CbGpPWpGaD
Cladribine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0013	0.0026	CcSEcCtD
Cladribine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00129	0.0026	CcSEcCtD
Cladribine—RRM2—Cell Cycle—EMD—dilated cardiomyopathy	0.00129	0.00424	CbGpPWpGaD
Cladribine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00129	0.00259	CcSEcCtD
Cladribine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00128	0.00257	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.00128	0.0042	CbGpPWpGaD
Cladribine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00128	0.00256	CcSEcCtD
Cladribine—Asthenia—Furosemide—dilated cardiomyopathy	0.00126	0.00253	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00126	0.00413	CbGpPWpGaD
Cladribine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00126	0.00253	CcSEcCtD
Cladribine—Pruritus—Furosemide—dilated cardiomyopathy	0.00124	0.0025	CcSEcCtD
Cladribine—POLE—Cell Cycle—EMD—dilated cardiomyopathy	0.00124	0.00407	CbGpPWpGaD
Cladribine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00123	0.00248	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—PSEN2—dilated cardiomyopathy	0.00122	0.004	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00121	0.00398	CbGpPWpGaD
Cladribine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0012	0.00242	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0012	0.00241	CcSEcCtD
Cladribine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00119	0.0024	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—EGFR—dilated cardiomyopathy	0.00119	0.00389	CbGpPWpGaD
Cladribine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00118	0.00238	CcSEcCtD
Cladribine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00118	0.00236	CcSEcCtD
Cladribine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00117	0.00236	CcSEcCtD
Cladribine—POLE—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00117	0.00382	CbGpPWpGaD
Cladribine—Dizziness—Furosemide—dilated cardiomyopathy	0.00116	0.00234	CcSEcCtD
Cladribine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00115	0.0023	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TMPO—dilated cardiomyopathy	0.00114	0.00375	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00114	0.00229	CcSEcCtD
Cladribine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00114	0.00229	CcSEcCtD
Cladribine—Pain—Lisinopril—dilated cardiomyopathy	0.00113	0.00227	CcSEcCtD
Cladribine—Constipation—Lisinopril—dilated cardiomyopathy	0.00113	0.00227	CcSEcCtD
Cladribine—Vomiting—Furosemide—dilated cardiomyopathy	0.00112	0.00225	CcSEcCtD
Cladribine—Rash—Furosemide—dilated cardiomyopathy	0.00111	0.00223	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00111	0.00363	CbGpPWpGaD
Cladribine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00111	0.00223	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.0011	0.00362	CbGpPWpGaD
Cladribine—Headache—Furosemide—dilated cardiomyopathy	0.0011	0.00221	CcSEcCtD
Cladribine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00109	0.00218	CcSEcCtD
Cladribine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00108	0.00217	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00107	0.00352	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.00105	0.00345	CbGpPWpGaD
Cladribine—Urticaria—Lisinopril—dilated cardiomyopathy	0.00105	0.00211	CcSEcCtD
Cladribine—Nausea—Furosemide—dilated cardiomyopathy	0.00104	0.0021	CcSEcCtD
Cladribine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00104	0.0021	CcSEcCtD
Cladribine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00104	0.0021	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00104	0.0034	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00103	0.00339	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NR3C2—dilated cardiomyopathy	0.00103	0.00336	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00101	0.00332	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000996	0.00327	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TUBB—dilated cardiomyopathy	0.000991	0.00325	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000988	0.00324	CbGpPWpGaD
Cladribine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000972	0.00195	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00097	0.00318	CbGpPWpGaD
Cladribine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000947	0.0019	CcSEcCtD
Cladribine—POLE2—Cell Cycle—LMNA—dilated cardiomyopathy	0.000939	0.00308	CbGpPWpGaD
Cladribine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000934	0.00188	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.000929	0.00305	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.000905	0.00297	CbGpPWpGaD
Cladribine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000903	0.00181	CcSEcCtD
Cladribine—RRM1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000889	0.00292	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—EMD—dilated cardiomyopathy	0.000883	0.0029	CbGpPWpGaD
Cladribine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000873	0.00175	CcSEcCtD
Cladribine—SLC22A2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000868	0.00285	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000859	0.00282	CbGpPWpGaD
Cladribine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000839	0.00169	CcSEcCtD
Cladribine—RRM1—Metabolism—TAZ—dilated cardiomyopathy	0.000836	0.00274	CbGpPWpGaD
Cladribine—Rash—Lisinopril—dilated cardiomyopathy	0.000832	0.00167	CcSEcCtD
Cladribine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000831	0.00167	CcSEcCtD
Cladribine—POLA1—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00083	0.00272	CbGpPWpGaD
Cladribine—Headache—Lisinopril—dilated cardiomyopathy	0.000827	0.00166	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000824	0.0027	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000809	0.00265	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000789	0.00259	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.000785	0.00258	CbGpPWpGaD
Cladribine—Nausea—Lisinopril—dilated cardiomyopathy	0.000784	0.00157	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TMPO—dilated cardiomyopathy	0.000768	0.00252	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000763	0.0025	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SDHA—dilated cardiomyopathy	0.000756	0.00248	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TMPO—dilated cardiomyopathy	0.000737	0.00242	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000735	0.00241	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000732	0.0024	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00071	0.00233	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000705	0.00231	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000693	0.00227	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TAZ—dilated cardiomyopathy	0.000688	0.00226	CbGpPWpGaD
Cladribine—DCK—Metabolism—ANKRD1—dilated cardiomyopathy	0.000684	0.00224	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000677	0.00222	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000672	0.0022	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000665	0.00218	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CD36—dilated cardiomyopathy	0.000651	0.00213	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—ABCC9—dilated cardiomyopathy	0.000646	0.00212	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.000645	0.00212	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NPPA—dilated cardiomyopathy	0.000644	0.00211	CbGpPWpGaD
Cladribine—DCK—Metabolism—TAZ—dilated cardiomyopathy	0.000643	0.00211	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—LMNA—dilated cardiomyopathy	0.000631	0.00207	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SDHA—dilated cardiomyopathy	0.000622	0.00204	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—ACTN2—dilated cardiomyopathy	0.00062	0.00203	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—RAC1—dilated cardiomyopathy	0.000613	0.00201	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—LMNA—dilated cardiomyopathy	0.000605	0.00199	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000604	0.00198	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000587	0.00193	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000582	0.00191	CbGpPWpGaD
Cladribine—DCK—Metabolism—SDHA—dilated cardiomyopathy	0.000582	0.00191	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000571	0.00187	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TMPO—dilated cardiomyopathy	0.000525	0.00172	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000482	0.00158	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000461	0.00151	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000439	0.00144	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—LMNA—dilated cardiomyopathy	0.000431	0.00141	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000417	0.00137	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GPX1—dilated cardiomyopathy	0.000412	0.00135	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000412	0.00135	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—RAF1—dilated cardiomyopathy	0.000407	0.00133	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000405	0.00133	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000405	0.00133	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CD36—dilated cardiomyopathy	0.000402	0.00132	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000401	0.00132	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000401	0.00132	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000384	0.00126	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000378	0.00124	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000377	0.00124	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000374	0.00123	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000374	0.00123	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000373	0.00122	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AGT—dilated cardiomyopathy	0.000362	0.00119	CbGpPWpGaD
Cladribine—PNP—Metabolism—GPX1—dilated cardiomyopathy	0.000358	0.00117	CbGpPWpGaD
Cladribine—PNP—Metabolism—CD36—dilated cardiomyopathy	0.000348	0.00114	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000347	0.00114	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000327	0.00107	CbGpPWpGaD
Cladribine—PNP—Metabolism—AGT—dilated cardiomyopathy	0.000314	0.00103	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—dilated cardiomyopathy	0.000279	0.000914	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000274	0.000898	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000271	0.000889	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TNF—dilated cardiomyopathy	0.000266	0.000871	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00026	0.000851	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	0.000257	0.000844	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TAZ—dilated cardiomyopathy	0.000255	0.000835	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000253	0.000828	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000247	0.000811	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TAZ—dilated cardiomyopathy	0.000237	0.000779	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	0.000233	0.000763	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SDHA—dilated cardiomyopathy	0.00023	0.000756	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SDHA—dilated cardiomyopathy	0.000215	0.000704	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GPX1—dilated cardiomyopathy	0.000205	0.000673	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CD36—dilated cardiomyopathy	0.0002	0.000656	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000197	0.000647	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000184	0.000603	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AGT—dilated cardiomyopathy	0.00018	0.00059	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GPX1—dilated cardiomyopathy	0.000169	0.000555	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CD36—dilated cardiomyopathy	0.000165	0.00054	CbGpPWpGaD
Cladribine—DCK—Metabolism—GPX1—dilated cardiomyopathy	0.000158	0.000518	CbGpPWpGaD
Cladribine—DCK—Metabolism—CD36—dilated cardiomyopathy	0.000154	0.000505	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—RAF1—dilated cardiomyopathy	0.000151	0.000496	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AGT—dilated cardiomyopathy	0.000148	0.000486	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—RAF1—dilated cardiomyopathy	0.000141	0.000462	CbGpPWpGaD
Cladribine—DCK—Metabolism—AGT—dilated cardiomyopathy	0.000139	0.000454	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.22e-05	0.000269	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.13e-05	0.000267	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.58e-05	0.000249	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	6.32e-05	0.000207	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX1—dilated cardiomyopathy	6.26e-05	0.000205	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CD36—dilated cardiomyopathy	6.16e-05	0.000202	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CD36—dilated cardiomyopathy	6.1e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX1—dilated cardiomyopathy	5.83e-05	0.000191	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CD36—dilated cardiomyopathy	5.68e-05	0.000186	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AGT—dilated cardiomyopathy	5.55e-05	0.000182	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AGT—dilated cardiomyopathy	5.49e-05	0.00018	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AGT—dilated cardiomyopathy	5.12e-05	0.000168	CbGpPWpGaD
